Is there an inherent limit to acute migraine treatment efficacy?
Bigal
Marcelo E
ME
Merck Research Laboratories, Whitehouse Station, NJ, USA. marcelo_bigal@merck.com
Ho
Tony W
TW
D001381:Azepines / Q000494:pharmacology* / Q000627:therapeutic use; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards; D004151:Dipeptides / Q000494:pharmacology* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D023381:Endpoint Determination / Q000379:methods / Q000592:standards; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D008881:Migraine Disorders / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D010879:Piperazines; D011799:Quinazolines / Q000494:pharmacology* / Q000627:therapeutic use; D018015:Receptors, Calcitonin Gene-Related Peptide / Q000378:metabolism; D017366:Serotonin Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014363:Tryptamines / Q000494:pharmacology / Q000627:therapeutic use
D001381:Azepines; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D004151:Dipeptides; D007093:Imidazoles; D010879:Piperazines; D011799:Quinazolines; D018015:Receptors, Calcitonin Gene-Related Peptide; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C525458:telcagepant; C406305:olcegepant